Tenalisib

Tenalisib is a drug under investigation for treating relapsed/refractory lymphoid malignancies, particularly T-cell lymphomas, and has shown potential in breast cancer and other hematologic cancers. It works by inhibiting the phosphoinositide 3-kinase delta and gamma (PI3Kδ/γ) and salt-inducible kinase 3 (SIK3), which reduces tumor cell proliferation, induces apoptosis (programmed cell death), and modulates the tumor microenvironment. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include tenalisibum and (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one. Its PubChem CID is 86291103.

CAS No 1639417-53-0
Molecular Formula C23H18FN5O2
Molecular Weight 415.4 g/mol
Synonyms 3-(3-fluorophenyl)-2-[(1S)-1-(7H-purin-6-ylamino)propyl]chromen-4-one

Frequently Asked Questions